Exchange: NASDAQ·Updated 07:55 PM EDT

ROIV News

News
all
press releases
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.
Stocktwits
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.
Stocktwits
More News
Here's How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an annualized basis producing an average annual return of 39.09%. Currently, Roivant Sciences has a market capitalization ofread more...
Benzinga
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today?
Investors rewarded three very different catalysts spanning artificial intelligence, biotechnology, and energy.
Stocktwits
Stocks Making Noise as the Market Hunts for Its Next Big Winners
The small-cap market is serving up a mix of stories centered on PDS Biotech (NASDAQ:PDSB), NeOnc (NASDAQ:NTHI), CEA Industries (NASDAQ:BNC), Bluejay Diagnostics (NASDAQ:BJDX), NuRAN Wireless (NASDAQ:NUR) and Roivant Sciences (NASDAQ:ROIV).
24-7 Market News
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?
Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.
Stocktwits
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.read more...
Benzinga
Roivant’s Experimental Lung Disease Drug Hits Key Phase 2 Goal – ROIV Stock Tracks All-Time High
Roivant’s Mosliciguat reduced pulmonary vascular resistance by 56.3% compared with placebo after 16 weeks.
Stocktwits
ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.
Stocktwits
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimates
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +27.78% and +4.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.